Outlook Therapeutics (OTLK) said Thursday it submitted a biologics license application to the Food and Drug Administration for its ONS-5010 investigational...
Kurt J Hilzinger, Director, on February 22, 2022, executed a purchase for 175,132 shares in Outlook Therapeutics (OTLK) for $256,970. Following the Form 4...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Ghiath M. Sukhtian, 10% Owner, Director, on November 29, 2021, executed a purchase for 16,000,000 shares in Outlook Therapeutics (OTLK) for $20,000,000....
Outlook Therapeutics (OTLK) on Tuesday increased its previously announced bought-deal offering of common shares to $50 million in gross proceeds from the...
Outlook Therapeutics (OTLK) said late Tuesday it agreed to a bought-deal offering of common stock allowing underwriter HC Wainwright to buy 8 million...
Outlook Therapeutics (OTLK) said Tuesday its ophthalmic formulation of bevacizumab for retinal indications produced "strong" safety data consistent with...
Outlook Therapeutics (OTLK) said Tuesday its ONS-5010 drug being developed for the potential treatment of age-related macular degeneration showed its...
Outlook Therapeutics (OTLK) said Tuesday that ONS-5010 met both of its primary and secondary endpoints in a phase 3 trial in patients with neovascular...
US stocks were set for a cautiously higher open Tuesday, staging a slight recovery after tumbling in the previous session as US manufacturing sentiment...